Childhood onset systemic lupus erythematosus: how is it different from adult SLE?
Identifieur interne : 000F72 ( Main/Exploration ); précédent : 000F71; suivant : 000F73Childhood onset systemic lupus erythematosus: how is it different from adult SLE?
Auteurs : Amita Aggarwal [Inde] ; Puja Srivastava [Inde]Source :
- International Journal of Rheumatic Diseases [ 1756-1841 ] ; 2015-02.
Abstract
About 20% of systemic lupus erythematosus (SLE) starts in childhood and children have less gender bias in favor of females as compared to adults. Systemic manifestations, nephritis, neuro‐psychiatric disease and cytopenias are more common in children at presentation than adults. Since most children develop lupus in their early adolescence, dealing with the diagnosis of an unpredictable lifelong disease during this phase of life is challenging. Physicians must recognise specific medical and social needs of this age group, for optimal long‐term outcome. Steroids and immunosuppressive drugs are the cornerstone for treatment in children as with adults with lupus. The outcome has improved considerably with these drugs and 10‐year survival is nearly 90%. Due to longer life spans more damage accrues in children as compared to adults. Most of the drugs are associated with significant toxicity and the goal of having a drug which reduces disease activity and damage without hampering normal growth, development and fertility is still an elusive one. The current review focuses on clinical and immunological aspects of childhood SLE and how it differs from adulthood SLE.
Url:
DOI: 10.1111/1756-185X.12419
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000387
- to stream Istex, to step Curation: 000387
- to stream Istex, to step Checkpoint: 000117
- to stream Main, to step Merge: 000F73
- to stream Main, to step Curation: 000F72
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Childhood onset systemic lupus erythematosus: how is it different from adult SLE?</title><author><name sortKey="Aggarwal, Amita" sort="Aggarwal, Amita" uniqKey="Aggarwal A" first="Amita" last="Aggarwal">Amita Aggarwal</name></author><author><name sortKey="Srivastava, Puja" sort="Srivastava, Puja" uniqKey="Srivastava P" first="Puja" last="Srivastava">Puja Srivastava</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:32B04E3511E4627174CC227B868DB3EF43A405ED</idno><date when="2015" year="2015">2015</date><idno type="doi">10.1111/1756-185X.12419</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-DK7DLW8H-K/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000387</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000387</idno><idno type="wicri:Area/Istex/Curation">000387</idno><idno type="wicri:Area/Istex/Checkpoint">000117</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000117</idno><idno type="wicri:doubleKey">1756-1841:2015:Aggarwal A:childhood:onset:systemic</idno><idno type="wicri:Area/Main/Merge">000F73</idno><idno type="wicri:Area/Main/Curation">000F72</idno><idno type="wicri:Area/Main/Exploration">000F72</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Childhood onset systemic lupus erythematosus: how is it different from adult SLE?</title><author><name sortKey="Aggarwal, Amita" sort="Aggarwal, Amita" uniqKey="Aggarwal A" first="Amita" last="Aggarwal">Amita Aggarwal</name><affiliation wicri:level="1"><country xml:lang="fr">Inde</country><wicri:regionArea>Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow</wicri:regionArea><wicri:noRegion>Lucknow</wicri:noRegion></affiliation><affiliation></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Inde</country></affiliation></author><author><name sortKey="Srivastava, Puja" sort="Srivastava, Puja" uniqKey="Srivastava P" first="Puja" last="Srivastava">Puja Srivastava</name><affiliation wicri:level="1"><country xml:lang="fr">Inde</country><wicri:regionArea>Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow</wicri:regionArea><wicri:noRegion>Lucknow</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">International Journal of Rheumatic Diseases</title><title level="j" type="sub">Special issue on LUPUS in the Asia‐Pacific region</title><title level="j" type="alt">INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES</title><idno type="ISSN">1756-1841</idno><idno type="eISSN">1756-185X</idno><imprint><biblScope unit="vol">18</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="182">182</biblScope><biblScope unit="page" to="191">191</biblScope><biblScope unit="page-count">10</biblScope><date type="published" when="2015-02">2015-02</date></imprint><idno type="ISSN">1756-1841</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1756-1841</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract">About 20% of systemic lupus erythematosus (SLE) starts in childhood and children have less gender bias in favor of females as compared to adults. Systemic manifestations, nephritis, neuro‐psychiatric disease and cytopenias are more common in children at presentation than adults. Since most children develop lupus in their early adolescence, dealing with the diagnosis of an unpredictable lifelong disease during this phase of life is challenging. Physicians must recognise specific medical and social needs of this age group, for optimal long‐term outcome. Steroids and immunosuppressive drugs are the cornerstone for treatment in children as with adults with lupus. The outcome has improved considerably with these drugs and 10‐year survival is nearly 90%. Due to longer life spans more damage accrues in children as compared to adults. Most of the drugs are associated with significant toxicity and the goal of having a drug which reduces disease activity and damage without hampering normal growth, development and fertility is still an elusive one. The current review focuses on clinical and immunological aspects of childhood SLE and how it differs from adulthood SLE.</div></front></TEI><affiliations><list><country><li>Inde</li></country></list><tree><country name="Inde"><noRegion><name sortKey="Aggarwal, Amita" sort="Aggarwal, Amita" uniqKey="Aggarwal A" first="Amita" last="Aggarwal">Amita Aggarwal</name></noRegion><name sortKey="Aggarwal, Amita" sort="Aggarwal, Amita" uniqKey="Aggarwal A" first="Amita" last="Aggarwal">Amita Aggarwal</name><name sortKey="Srivastava, Puja" sort="Srivastava, Puja" uniqKey="Srivastava P" first="Puja" last="Srivastava">Puja Srivastava</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F72 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000F72 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:32B04E3511E4627174CC227B868DB3EF43A405ED
|texte= Childhood onset systemic lupus erythematosus: how is it different from adult SLE?
}}
| This area was generated with Dilib version V0.6.33. |  |